公开(公告)号：US20110274688A1

公开(公告)日：2011-11-10

申请号：US13186299

申请日：2011-07-19

Applicant: Mark I. Greene ,  Makoto Katsumata ,  Jeffrey Drebin

Inventor： Mark I. Greene ,  Makoto Katsumata ,  Jeffrey Drebin

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/32 ,  A61K38/00 ,  A61K2039/505

Abstract: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.

Abstract translation: 公开了防止正常细胞向其表面具有p185的肿瘤细胞转化的方法。 所述方法包括施用特异性结合p185的抗体。 公开了防止正常细胞转化成肿瘤细胞的方法，所述肿瘤细胞在具有高发展肿瘤风险的个体的表面上具有p185。

公开(公告)号：US20100239587A1

公开(公告)日：2010-09-23

申请号：US12787594

申请日：2010-05-26

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang ,  Mark Richter ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Hongtao Zhang ,  Mark Richter ,  Alan Berezov ,  Qingdu Liu ,  Jinqiu Chen

IPC: A61K39/395 ,  C07K16/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K47/48238 ,  A61K47/4833 ,  A61K47/48384 ,  A61K47/48407 ,  A61K47/48507 ,  A61K47/62 ,  A61K47/646 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6835 ,  A61K51/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7151 ,  C07K14/82

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract translation: 描述了erbB，TNF和IgSF受体的肽，模拟物和抗体以及包含其的药物组合物。 公开了在治疗，预防，成像和诊断应用中使用这些抗体，肽和模拟物的方法。

公开(公告)号：US07653495B1

公开(公告)日：2010-01-26

申请号：US09720647

申请日：1999-07-01

Applicant: Ramachandran Murali ,  Mark I. Greene

Inventor： Ramachandran Murali ,  Mark I. Greene

IPC: G01N31/00 ,  A61K38/00 ,  C07K1/00 ,  G01N33/566

CPC classification number: A61K31/655 ,  A61K8/42 ,  A61K31/17 ,  A61K31/40 ,  G01N33/573 ,  G01N33/68 ,  G01N2500/02

Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.

Abstract translation: 公开了鉴定调节靶蛋白和修饰剂之间的分子间相互作用的化合物的方法。 公开了包含抑制靶蛋白和修饰剂之间的分子间相互作用的化合物的药物组合物。 公开了治疗患有炎性病症，不良免疫应答，免疫学条件和细菌感染的个体的方法。

公开(公告)号：US07566741B2

公开(公告)日：2009-07-28

申请号：US10625073

申请日：2003-07-22

Applicant: Mark I. Greene ,  Ramachandran Murali ,  Masahiko Kinosaki

Inventor： Mark I. Greene ,  Ramachandran Murali ,  Masahiko Kinosaki

IPC: A61K31/05 ,  A61K31/03 ,  A61K31/085 ,  A61K31/131 ,  A61P19/08 ,  A61P19/10

CPC classification number: C07K14/70575 ,  A61K31/00 ,  A61K31/03 ,  A61K31/235 ,  A61K31/565 ,  A61K31/585 ,  A61K38/1709 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1021

Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Abstract translation: 公开了抑制破骨细胞发生的方法和破骨细胞的活性。 公开了治疗具有骨丢失特征的患者的方法。 根据该方法，向患者施用一定量的有效抑制破骨细胞发生的TRANCE / RANK抑制剂。 含有有效抑制破骨细胞发生量的TRANCE / RANK抑制剂的药物组合物。 公开了调节个体中树突状细胞成熟，T细胞增殖和/或CD40受体系统的方法。 所述方法包括向个体施用一定量的有效调节树突状细胞成熟，T细胞增殖和/或CD40受体系统的TRANCE / RANK抑制剂的步骤。

公开(公告)号：US20090010935A1

公开(公告)日：2009-01-08

申请号：US12114475

申请日：2008-05-02

Applicant: Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong-Woo Park

Inventor： Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong-Woo Park

IPC: A61K39/395 ,  A61K31/7088 ,  A61P35/00

CPC classification number: C07K16/32 ,  A61K38/1709 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/572 ,  A61N5/10 ,  C07K14/71 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2300/00

Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.

Abstract translation: 公开了治疗患有erbB蛋白介导的肿瘤的个体的方法。 公开了预防个体中erbB蛋白介导的肿瘤的方法。 所述方法包括向个体施用编码与erbB蛋白二聚化并且缺乏酪氨酸激酶活性的蛋白质的核酸分子。 公开了包含这种核酸分子（包括药物组合物）的组合物。

公开(公告)号：US06740665B1

公开(公告)日：2004-05-25

申请号：US09913128

申请日：2002-03-12

Applicant: Ramachandran Murali ,  Mark I. Greene

Inventor： Ramachandran Murali ,  Mark I. Greene

IPC: A61K3147

CPC classification number: A61K45/06 ,  A61K31/35 ,  A61K31/36 ,  A61K31/47 ,  A61K2300/00

Abstract: Tyrosine kinase inhibitors and pharmaceutical composition comprising the same are disclosed. Methods of treating mammals who have p185 tumors and methods of preventing p185 tumors in mammals at elevated risks of developing such tumors are disclosed. The methods comprise the step of administering effective amounts pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and, a tyrosine kinase inhibitor to the mammal.

Abstract translation: 公开了酪氨酸激酶抑制剂和包含其的药物组合物。 公开了治疗具有p185肿瘤的哺乳动物的方法和在发展这种肿瘤的风险升高的哺乳动物中预防p185肿瘤的方法。 所述方法包括向哺乳动物施用包含药学上可接受的载体或稀释剂和酪氨酸激酶抑制剂的有效量的药物组合物的步骤。

公开(公告)号：US5338829A

公开(公告)日：1994-08-16

申请号：US932078

申请日：1992-10-19

Applicant: David B. Weiner ,  Mark I. Greene ,  William V. Williams

Inventor： David B. Weiner ,  Mark I. Greene ,  William V. Williams

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/16 ,  C07K14/705 ,  C07K16/10 ,  A61K37/02 ,  C07K3/00 ,  C07K5/00 ,  C07K15/00

CPC classification number: C07K14/005 ,  C07K14/705 ,  C07K16/1063 ,  A61K38/00 ,  A61K39/00 ,  C12N2740/16122

Abstract: This invention discloses novel polypeptides having an antigenic determinant or determinants immunologically cross-reactive with determinants of a glycoprotein having a molecular weight of approximately 41,000 daltons, and determinants of a glycoprotein having a molecular weight of approximately 160,000 daltons which are obtained from cells infected with human immunodeficiency virus-1. The invention further discloses novel polypeptides having an antigenic determinant or determinants specific for a glycoprotein having a molecular weight of approximately 41,000 daltons obtained from cells infected with human immunodeficiency virus-1, the polypeptides further having an antigenic determinant or determinants immunologically cross-reactive with at least one glycoprotein having a molecular weight of 25,000 to 35,000 daltons, 45,000 daltons to 60,000 daltons, 80,000 to 100,000 daltons or 180,000 or 220,000 daltons, which are obtained from HSB, St, HeLa and human cells. The novel polypeptides of the invention are useful in methods of interfering with the effects of HIV-1 upon host cells having cell surface polypeptides capable of binding HIV-1. Methods of assay for HIV-1 infection are also disclosed. The invention also discloses peptides having amino acid sequences of about 10 to about 50 amino acids that correspond to at least a portion of an epitope of HIV and methods for developing such biologically active peptides.

Abstract translation: 本发明公开了具有与具有约41,000道尔顿分子量的糖蛋白的决定簇免疫交叉反应的抗原决定簇或决定簇的新型多肽，以及分子量约为160,000道尔顿的糖蛋白的决定簇，这些糖蛋白是从感染人的细胞获得的 免疫缺陷病毒-1。 本发明进一步公开了具有抗原决定簇或具有特异性的决定簇的新型多肽，该决定簇具有从感染人类免疫缺陷病毒-1的细胞获得的具有约41,000道尔顿的糖蛋白的特异性，所述多肽还具有抗原决定簇或与抗原决定簇免疫交叉反应的决定簇 至少一种由HSB，St，HeLa和人细胞获得的分子量为25,000至35,000道尔顿，45,000道尔顿至60,000道尔顿，80,000至100,000道尔顿或180,000或220,000道尔顿的糖蛋白。 本发明的新型多肽可用于干扰HIV-1对具有能够结合HIV-1的细胞表面多肽的宿主细胞的作用的方法。 还公开了HIV-1感染的测定方法。 本发明还公开了具有对应于HIV表位的至少一部分的约10至约50个氨基酸的氨基酸序列的肽和用于开发此类生物活性肽的方法。

公开(公告)号：US20160289334A2

公开(公告)日：2016-10-06

申请号：US14729798

申请日：2015-06-03

Applicant: Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong Woo Park

Inventor： Mark I. Greene ,  Donald M. O'Rourke ,  Ramachandran Murali ,  Byeong Woo Park

IPC: C07K16/32 ,  A61K45/06 ,  A61N5/10 ,  A61K39/395

CPC classification number: C07K16/32 ,  A61K38/1709 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/572 ,  A61N5/10 ,  C07K14/71 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2300/00

Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.

公开(公告)号：US20120164066A1

公开(公告)日：2012-06-28

申请号：US13262060

申请日：2010-03-31

Applicant: Mark I. Greene ,  Hongtao Zhang ,  Xiaomin Song ,  Ramachandran Murali ,  Masahide Tone

Inventor： Mark I. Greene ,  Hongtao Zhang ,  Xiaomin Song ,  Ramachandran Murali ,  Masahide Tone

IPC: A61K51/10 ,  C07K19/00 ,  C12N15/62 ,  A61K39/395 ,  A61K49/00 ,  C12N5/10 ,  C07K14/00 ,  G01N33/574 ,  A61P35/00 ,  G01N33/566 ,  C12N9/96 ,  C12N1/21

CPC classification number: A61K38/16 ,  A61K49/00 ,  C07K1/22 ,  C07K14/70596 ,  C07K16/2896 ,  C07K19/00 ,  C07K2319/30 ,  G01N33/53

Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Abstract translation: 本文公开了用于产生抗原结合蛋白的重组蛋白质支架和重组多功能蛋白质支架。此外，提供了编码这种重组蛋白质支架的核酸，重组多功能蛋白质支架和抗原结合蛋白。用于表达 还提供了所描述的蛋白质，以及使用方法。

公开(公告)号：US08019557B2

公开(公告)日：2011-09-13

申请号：US12632221

申请日：2009-12-07

Applicant: Ramachandran Murali ,  Mark I. Greene

Inventor： Ramachandran Murali ,  Mark I. Greene

IPC: G01N31/00 ,  G01N33/566 ,  A61K38/00 ,  C07K1/00

CPC classification number: A61K31/655 ,  A61K8/42 ,  A61K31/17 ,  A61K31/40 ,  G01N33/573 ,  G01N33/68 ,  G01N2500/02

Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.

Abstract translation: 公开了鉴定调节靶蛋白和修饰剂之间的分子间相互作用的化合物的方法。 公开了包含抑制靶蛋白和修饰剂之间的分子间相互作用的化合物的药物组合物。 公开了治疗患有炎性病症，不良免疫应答，免疫学条件和细菌感染的个体的方法。